53 results about "Mitochondrial targeting" patented technology

The invention relates to the technical field of biomedical materials, in particular to an alendronate-modified ZIF-8 encapsulated TPP-carbon dot bone targeting nano-material and a preparation method and application thereof.The alendronate-modified ZIF-8 serves as a carrier, TPP-modified carbon dots are encapsulated in the carrier, citric acid, urea and cerium salt serve as raw materials of the TPP-modified carbon dots, and the alendronate-modified ZIF-8 encapsulated TPP-carbon dot bone targeting nano-material is prepared through a one-step method. After cerium-doped carbon quantum dots are synthesized through a hydrothermal method, TPP is grafted through an amide method, alendronate endows the material with a bone targeting function, and TPP modified carbon dots endow the material with antioxidant and mitochondrial targeting functions. According to the invention, the bone targeting property is excellent, and bone focuses are efficiently enriched; the anti-oxidation and anti-inflammatory capacities are high, and the infected microenvironment can be improved; zIF-8 packaging is stable, and functional components can be controllably released; multiple components cooperate to promote bone repair, accumulation of non-target organs is little, and the composition is safe, reliable and suitable for treatment of various bone-related diseases.

The application discloses a green preparation method of a medium-chain acylated hydroxytyrosol lipoid-triphenylphosphine derivative and application of the derivative in mitochondrial-targeted antioxidation, and relates to the following steps: taking hydroxytyrosol and saturated halogenated fatty acids with medium-chain length C8-C12 as raw materials, and synthesizing a medium-chain hydroxytyrosol lipoid compound through a low-field ultrasonic coupling immobilized lipase synergistic directional alcohol hydroxyl acylation reaction; and further synthesizing the lipoid compound through high-speed stirring reaction with a triphenylphosphine compound to obtain a medium-chain acylated hydroxytyrosol lipoid-triphenylphosphine derivative. The derivative has the antioxidation effect of mitochondrial-targeted enrichment and active oxygen radical scavenging. The hydroxytyrosol derivative prepared by the application has the characteristics of green efficiency, directional bonding and simple operation. The acylation reaction of hydroxytyrosol does not need to involve flammable and explosive, easily oxidized and corrosive concentrated sulfuric acid and concentrated nitric acid, and the medium-chain acylated hydroxytyrosol lipoid-triphenylphosphine derivative has mitochondrial targeting, can be used as a potential mitochondrial nutritional supplement product, and has a wide application prospect in the health care functions of anti-aging, cardiovascular protection, diabetes prevention and the like.

This invention relates to the field of bionanomaterials technology, and particularly to mitochondrial-targeting nanomaterials capable of releasing HNO, their preparation methods, and applications. The preparation method of the mitochondrial-targeting nanomaterials capable of releasing HNO includes the following steps: synthesis of a silanized HNO donor: hydroxylamine hydrochloride is dissolved in a mixed solvent of anhydrous tetrahydrofuran and anhydrous pyridine, and a dichloromethane solution of 2-(4-chlorosulfonylphenyl)ethyltrimethoxysilane is added. The mixture is stirred at room temperature, and after post-treatment, a silanized HNO donor is obtained; synthesis of aminated carbon dots: chitosan, ethylenediamine, and mercaptosuccinic acid are dispersed in deionized water, and concentrated hydrochloric acid is added and stirred until dissolved. This preparation method can prepare mitochondrial-targeting nanomaterials capable of releasing HNO, achieving precise delivery, controlled release, and visual tracking of HNO to cardiac mitochondria, solving the technical problems of traditional HNO donors' inability to achieve stable loading on carriers and lack of mitochondrial targeting ability.

The present invention relates to base editing of mitochondrial DNA. More specifically, the present invention relates to: a method for editing mitochondrial DNA bases by using a mitochondrial targeting sequence (MTS); and a base editing system used in the method. The base editing system comprises a DNA binding protein and a deaminase, or polynucleotides encoding these, and does not include an affinity tag or a polynucleotide encoding same. The present invention is useful for editing mitochondrial DNA bases of animal cells or plant cells.

The invention discloses a fluorescent probe for high-sensitivity monitoring of cell mitochondrial autophagy as well as a preparation method and application thereof. The structure of the fluorescent probe is as shown in formula I in the specification. According to the fluorescent probe provided by the invention, a phenol group is used as an electron donor and a pH response unit, hydroxyl tricyanopyrrole is used as an electron acceptor, triphenylphosphine is used as a mitochondrial targeting group, fluorine atoms are introduced to a benzene ring to improve the response rate and the fluorescence intensity, and meanwhile, a thiophene ring is introduced to further expand the fluorescence emission wavelength. The probe can rapidly target mitochondria and emit corresponding fluorescence signals based on pH differences of different autophagy stages, so that real-time, high-sensitivity and high-selectivity monitoring of the mitochondria autophagy process is realized. In addition, the fluorescent probe is simple in molecular structure, small in molecular weight and easy to synthesize, purify and subsequently modify. Cell experiment results show that the probe can accurately trace the mitochondrial autophagy process in cells, and has good application potential in the field of biological imaging and detection.

The invention belongs to the field of fluorescent dyes and biological imaging, and particularly provides a mitochondrial targeting fluorescent dye as well as synthesis and application thereof. The structural formula of the mitochondrial targeting fluorescent dye is shown as a formula (I). The compound is synthesized by one-step heating reaction of benzothiazole-2-acetonitrile and Fisher's aldehyde under the action of alkali. The mitochondrial targeting fluorescent dye has good cell membrane penetrability, can be rapidly taken by cells, and is good in mitochondrial targeting, high in light stability and low in toxicity to the cells. Meanwhile, the preparation process is simple, the cost is low, clear and long-time fluorescence imaging analysis and dynamic fluorescence monitoring on mitochondria in cells can be realized, and the fluorescent probe has a good application prospect.

This invention discloses a near-infrared fluorescent probe for the rapid and sensitive detection of biothiols (Cys / Hcy) with a large Stokes shift targeting mitochondria. The structural formula of the fluorescent probe is shown in Formula (I). The probe of this invention not only exhibits rapid response time, high sensitivity, and selectivity to cysteine / homocysteine, but also a near-infrared emission response with a large Stokes shift (approximately 200 nm). Furthermore, this probe possesses good cell permeability and mitochondrial targeting ability, making it highly suitable for imaging and detection of Cys / Hcy in live cells.

To provide novel therapeutic compounds that target and inhibit a mitochondrial function, and may serve as anti-cancer therapeutics.SOLUTION: Alkyl-triphenylphosphonium compounds having a saturated, linear alkyl chain of about 9 to about 18 carbons may be used as therapeutic agents to treat cancer. Demonstrative compound dodecyl-TPP (d-TPP) dose-dependently inhibits the propagation of breast cancer stem cells and targets the bulk of the adherent of cancer cells, by decreasing MCF-7 cell viability. Further, d-TPP potently inhibits a mitochondrial oxygen consumption rate, while simultaneously shifting cell metabolism toward a glycolytic pathway. This shift to a strict metabolic dependency on glycolysis may be used to eradicate the residual glycolytic CSC population, by using additional metabolic stressors. For example, d-TPP may be combined with a glycolytic inhibitor or an OXPHOS inhibitor, through co-administration or sequential administration, to treat cancer and eradicate CSCs.SELECTED DRAWING: Figure 2

The invention relates to a nano drug delivery system loaded with nitazoxanide as well as a preparation method and application of the nano drug delivery system, and belongs to the technical field of pharmaceutical preparations. The nano drug delivery system is prepared by loading nitazoxanide on a metal organic framework ZIF-90 nano material through a simple and rapid method. The nano drug delivery system constructed by the invention can effectively improve the solubility and stability of nitazoxanide, and realizes the enrichment of drugs in tumor cell mitochondria by virtue of the mitochondrial targeting characteristic of the ZIF-90 material. The system can intelligently release drugs under the acidic and high ATP conditions of a tumor microenvironment, not only utilizes the metabolic reprogramming effect induced by nitazoxanide, but also synergistically enhances the anti-tumor effect in cooperation with the Zn < 2 + >-triggered oxidative stress disorder dual mechanism, and provides a new strategy for solving the problems of low bioavailability, poor targeting property and the like in clinical application of nitazoxanide.

The invention belongs to the technical field of medicines, and particularly relates to lactylphenylalanine liposome with mitochondrial targeting and fluorescent tracing functions and application of the lactylphenylalanine liposome in treatment of metabolism-related fatty liver diseases. The preparation method comprises the following steps: firstly, preparing a bifunctional molecule Cy5-Lac Phe, and covalently linking a therapeutic active component with a mitochondrial targeting fluorescent tracing group through a chemical bond to form a single multifunctional entity; therefore, each therapeutic molecule is ensured to have targeting and tracing capabilities, and the problems of non-uniform targeting efficiency and in-vivo dissociation caused by simple physical mixing of different components are solved. According to the invention, the bifunctional molecules are prepared into liposome nanoparticles. According to the liposome, passive liver targeting is achieved through the nanometer size of the liposome, so that free Cy5-Lac Phe molecules are efficiently enriched and released in the liver, a Cy5 module plays a mitochondrial targeting function, and accurate drug delivery at the organelle level is achieved. Meanwhile, the fluorescent tracing function of Cy5 allows real-time visual monitoring of the medicine.

The application designs a series of xanthene near-infrared mitochondrial fluorescent tracers, the self-assembly characteristics of the dyes are regulated by the length of the external hydrophobic carbon chain, and then the stability of the mitochondrial targeting and the signal-to-noise ratio of the imaging are optimized. The fluorescent tracers show strong NIR fluorescence, the emission wavelength can reach 700 nm, the molar extinction coefficient is 10.9 M ‑1 *cm ‑1 *10 4 , the fluorescence quantum yield is 0.64. In the aqueous phase, the ACQ effect is significant, but it can be quickly enriched and embedded into mitochondria, and then the strong fluorescence is restored, showing high signal-to-noise ratio; in living cells, it has stable mitochondrial targeting, is not affected by the membrane potential, and the imaging performance is better than that of the commercial probe TMRM. The fluorescent tracer can accurately and stably trace the microtubular morphological changes of mitochondria in ferroptosis.

The invention provides a preparation method and application of a polymitochondrial targeting peptide PSS31 and a lung targeting nucleic acid drug delivery system, and belongs to the technical field of biochemical synthesis pharmacy. According to the invention, SS31 is polymerized through TK to form a polymer material sensitive to ROS (reactive oxygen species), namely the polymer mitochondrial targeting peptide PSS31. The PSS31 not only can efficiently load a nucleic acid drug through an electrostatic adsorption effect, but also can efficiently release the nucleic acid drug under the stimulation of ROS in cells. According to the invention, on the basis of the PSS31, a fucoidin (Fuco) modified lung-targeted nucleic acid drug delivery system siHIF-1alpha / PSS31 (at) Fuco is prepared through an electrostatic adsorption effect. The siHIF-1alpha / PSS31 (at) Fuco can be used for efficiently loading the siHIF-1alpha, improving the stability of the siHIF-1alpha, relieving pulmonary vascular remodeling, reducing pulmonary arterial pressure and efficiently treating hypoxic pulmonary hypertension in multiple ways.

The present disclosure provides a mitochondrial targeting catalase or a variant thereof, a nucleic acid sequence encoding the mitochondrial targeting catalase or the variant thereof, a vector comprising the nucleic acid sequence, and a delivery system comprising the mitochondrial targeting catalase or the variant thereof and / or the nucleic acid sequence or the vector, a pharmaceutical or cosmetic composition comprising a mitochondrial targeting catalase or a variant thereof or such a nucleic acid sequence or a vector or a delivery system. The invention further provides a manufacturing method of the delivery system and application of the delivery system.

This invention relates to the field of photodynamic therapy for keloids, and discloses a mitochondrial-targeted photodynamic keloid therapeutic agent based on platinum complexes and its application. The agent is prepared by coordinating the organic ligand TBQQ with an activated cisplatin derivative in a 1:1 molar ratio, followed by column chromatography purification to produce a high-purity TBQQPt powder with an active ingredient purity ≥98%. The prepared TBQQPt powder is then administered through a standardized drug formulation, intratumoral administration, and photo-activation process, combined with a multi-dimensional efficacy monitoring and safety evaluation system. Leveraging the D-A type planar square coordination structure of TBQQPt, which endows it with type I / II mixed photodynamic reaction characteristics, mitochondrial targeting, and photocatalytic oxidation of NADH, it synergistically exerts a dual effect of energy deprivation and genome disruption, effectively inducing mitochondrial dysfunction and apoptosis of keloid fibroblasts, and inhibiting their proliferation.

The invention discloses a nucleic acid delivery carrier with targeting, active oxygen scavenging and gene delivery performance and application thereof, and belongs to the technical field of biological medicine. The core of the carrier is a double-selenium-bond-containing polyhydroxy branched cationic polymer prepared through amino-epoxy ring-opening polymerization, and the double-selenium-bond-containing polyhydroxy branched cationic polymer is clear in structure and controllable in molecular weight. The polymer can efficiently load nucleic acid to form stable nanoparticles, the diselenide bond of the polymer can specifically respond to a myocardial infarction area high-active oxygen environment, intelligent degradation and drug release are achieved, and active oxygen is synchronously removed. Furthermore, by grafting the heart targeting peptide CRPPR and the mitochondrial targeting peptide SS-31 and adopting a layer-by-layer self-assembly technology, a core-shell structure system is constructed, and when the polypeptide mass ratio is 1: 2, the system shows the optimal heart enrichment, mitochondrial targeting and oxidative stress protection synergistic ability. Animal experiments prove that the system can significantly improve the cardiac function after myocardial infarction.

This invention relates to the field of pharmaceutical chemistry, specifically to a Devimistat derivative with mitochondrial targeting function, its preparation method, and its application in antitumor drugs. This derivative covalently couples the mitochondrial-attractant 3-aminopropyl(triphenyl)phosphine bromide (TPP) group to the antitumor active molecule Devimistat, utilizing the affinity of the TPP cation for the mitochondrial transmembrane potential to drive the drug's specific accumulation in the mitochondrial matrix. While retaining the original drug's interference with the tricarboxylic acid cycle and inhibition of PDH and KGDH complex activity, this derivative significantly increases the effective drug concentration within tumor cells, thus solving the problem of limited efficacy of Devimistat due to its lack of targeting.

The invention belongs to the cross technical field of nano medicine, tumor immunotherapy and chemotherapy, and discloses a novel copper chelating nano medicine and a preparation method thereof. The preparation method of the novel copper chelating nano-drug comprises the following steps: S1, firstly, carrying out sulfydryl addition reaction on a mitochondrial targeting group by utilizing mercaptopropionic acid to prepare a mercaptopropionic acid intermediate; s2, coupling the thiohydracrylic acid intermediate with a copper ion chelating group through an amidation reaction to obtain a compound IR-TIE; and S3, carrying out self-assembly on the obtained IR-TIE and albumin to form the IR-TIE coated Alb nanoparticles. The compound has accurate tumor mitochondrial targeting property, free copper ions of tumor cells can be effectively reduced at an extremely low dosage, so that IDO1 and LOX are reduced, innate immune activation is realized, tumor collagen crosslinking is reduced, tumor extracellular matrix is loosened, and medicine permeation is promoted.

The invention discloses an iridium complex, a preparation method thereof and application of the iridium complex in chemoradiotherapy synergistic treatment. In the prior art, the design of systematic'combination of chemoradiotherapy and active targeting 'of iridium complexes and the report of clear mechanism-level evidence (such as gamma-H2AX, cell cycle and the like) are still limited. The invention discloses an iridium complex nano-drug and an application thereof in breast cancer chemoradiotherapy synergistic treatment, the iridium complex nano-drug has high atomic number elements and a targeting molecular nano-material, can enhance radiation energy deposition and enrich tumor tissues, and is a direction for improving radiotherapy sensitivity; the iridium complex has the characteristics of AIE performance, mitochondrial targeting, ROS production and the like, and is expected to be used as a chemotherapy sensitizer and an imaging probe.

This invention belongs to the field of photosensitizer delivery and photodynamic therapy technology, and discloses a TPP-modified PAMAM-loaded CyI mitochondrial-targeting nanophotosensitive system, its preparation method, and its applications. This invention aims to solve the problems of poor water dispersibility, insufficient in vivo stability, low delivery efficiency, and lack of mitochondrial targeting ability of CyI during application. The nanophotosensitive system consists of G5 generation PAMAM dendritic macromolecules, triphenylphosphine-based mitochondrial-targeting groups (TPP), and the near-infrared photosensitizer CyI. The preparation method involves first coupling TPP with G5 generation PAMAM to obtain a modified carrier, then mixing and purifying it with CyI to obtain the target nanophotosensitive system. This system is beneficial for improving the stability and delivery efficiency of CyI and enhancing its enrichment ability in tumor mitochondria, showing promising application prospects in tumor near-infrared fluorescence imaging and photodynamic therapy.

The application discloses a curcumin-based multilayer modified nano-liposome and a preparation method thereof. The method assembles a mitochondrial specific ligand hydrophobicization (3-propylcarboxyl) triphenylphosphonium bromide, a lysosome pH responsive substance histidine, a TLR4 / CD44 targeting ligand hyaluronic acid and a polyelectrolyte complex whey protein nanofiber and pectin from the inside to the outside layer by layer to the outer layer of a conventional nano-liposome to construct a multilayer modified nano-liposome for embedding curcumin. The curcumin-based multilayer modified nano-liposome has high drug embedding rate and physical stability, stronger mitochondrial targeting capacity and stronger anti-tumor capacity, can better overcome multiple physiological barriers of the body and realize efficient targeted delivery of curcumin to tumor cell mitochondria.

The invention relates to application of an OGN overexpression vector in preparation of a medicine for preventing reperfusion myocardial injury, and belongs to the technical field of biological medicine. Aiming at the problem that an existing mitochondrial targeting strategy is insufficient in multi-target cooperation in MI / RI prevention, the invention provides application of an OGN overexpression vector in preparation of drugs for preventing reperfusion myocardial injury, and the OGN overexpression vector is a recombinant adeno-associated virus vector and contains a nucleotide sequence for coding OGN. According to the invention, three-dimensional mitochondrial steady state regulation of myocardial ischemia reperfusion injury is realized for the first time, and myocardial energy metabolism is remarkably improved and cell death is reduced by enhancing mitochondrial respiratory chain activity, stabilizing membrane potential and inhibiting ROS outbreak, so that heart failure caused by MI / RI is effectively reversed. Experimental data confirm that AAV-mediated OGN overexpression has a protective effect on cardiac functions and has remarkable clinical transformation potential.

The invention belongs to the technical field of medicine, and particularly relates to a thiazolyl three-photon active covalent organic material and a preparation method and application thereof.The method comprises the steps that dithioacetamide and 1, 3, 5-triformyl benzene are utilized, a polymerization reaction of aldehyde groups and sulfamido groups is achieved through a catalyst-free one-pot method, a DT-COF nanowire of a D-A structure is synthesized, and the DT-COF nanowire with the D-A structure is obtained; according to the present invention, the thiazolothiazole-based DT-COF has good three-photon performance, and the thiazolothiazole-based DT-COF can avoid the pi-pi stacking interaction, can achieve the mitochondrial targeting ability, and can achieve the application in the aspects of multi-photon excitation tumor imaging and photodynamic therapy.

The invention belongs to the technical field of biological medicines, and particularly relates to a fluorinated polysarcosine mitochondrial targeting micelle as well as a preparation method and application thereof. A fluorine-containing alkyl chain is used as a hydrophobic block, polysarcosine is used as a hydrophilic block, the micelle is self-assembled, and the general formula of the micelle is shown in the formula (1), wherein m and n are positive integers. The preferable structure CF1-PPar24 of the fluorinated polysarcosine mitochondrial targeting micelle is that an alkyl chain is replaced by a fluorocarbon chain to optimize the micelle, so that the blood environment stability and the in-vivo circulation time of the micelle are improved, and the tumor tissue accumulation effect of a drug is enhanced; the neutral mitochondrial targeting carrier is constructed by adopting fluorocarbon chain-polysarcosine, so that the toxicity and off-target effect are reduced while the targeting property is retained, the application defect of PEG (Polyethylene Glycol) materials is avoided, and the purpose of improving the drug delivery performance is achieved.

This invention belongs to the field of pharmaceutical technology, specifically relating to a mitochondrial-targeting paclitaxel derivative, its preparation method, and its application. The paclitaxel derivative of this invention has the structure shown in Formula I: [Formula omitted]; where n is an integer from 2 to 8. The derivative exhibits tumor mitochondrial targeting, and compared to the same dose of paclitaxel, this derivative increases the inhibition rate of tumor cell growth, effectively inhibiting colon cancer cells and breast cancer cells, while reducing toxicity to normal cells, thus significantly reducing adverse drug reactions. It can be used as a new, highly effective, low-toxicity, broad-spectrum antitumor drug.

The invention discloses a liver / mitochondria dual-targeting carboxylesterase fluorescent probe as well as a preparation method and application thereof, and belongs to the technical field of medicines. The probe is a compound LDM-CA, has the liver and mitochondria dual-targeting characteristic, and shows high selectivity, sensitivity and strong binding affinity to CEs. In-vitro cell experiments show that the LDM-CA has excellent mitochondrial targeting ability in the HCC cells and specific fluorescence opening response to CEs in the cells, and can clearly distinguish the HCC cells from normal liver cells or non-liver cancer cells. In-vivo imaging of a mouse model shows that no matter in-tumor injection or intravenous injection, the LDM-CA can effectively visualize the HCC tumor and draw the edge of the tumor, has the prospect of serving as a powerful molecular tool for early HCC diagnosis and image-guided surgery, and also provides a valuable means for studying the action of mitochondrial CEs activity in HCC pathogenesis at the subcellular level.

The invention provides a tumor cell mitochondria targeting agent with a fluorescence co-localization function and a preparation method thereof, and belongs to the field of biomedicine. According to the method, triphenylamine is taken as a raw material, a pi conjugated skeleton is expanded by a benzothiadiazole bridging unit, pyridinium salt is taken as a strong electron acceptor, and different alkyl chains are connected, so that the mitochondrial targeting agent with aggregation-induced emission property is synthesized. The fluorescent mitochondrial targeting agent TBPMI not only has good biological safety, but also has good tumor cell mitochondrial selectivity and targeting accuracy, and the co-localization coefficient of the fluorescent mitochondrial targeting agent TBPMI and a commercial mitochondrial probe is as high as 0.96. Meanwhile, the prepared fluorescent mitochondrial targeting agent TBPMI has excellent aggregation-induced emission performance, and the aggregation-induced emission performance is obviously higher than that of a traditional commercial photosensitizer rose bengal. Therefore, the newly prepared fluorescent mitochondrial targeting agent TBPMI provides a new material for accurate positioning of organelle level under the guidance of a fluorescent image.

The invention belongs to the field of biomedical engineering, and particularly relates to a preparation method and application of a stem cell membrane bionic nano system. The invention provides a preparation method and application of a stem cell membrane bionic nano system. The system is endowed with excellent blood-brain barrier penetrating power and tumor active homing targeting property through stem cell membrane wrapping; by using the triphenylphosphine modified carbon dots, accurate mitochondrial targeting can be realized in the stem cell membrane bionic nano system, and apoptosis induction is enhanced; the stem cell membrane bionic nano system can realize integration of photo-thermal therapy, photodynamic therapy, nano-enzyme catalytic therapy and mitochondrial targeted therapy, multi-dimensionally kill tumor cells and destroy the steady state of a tumor microenvironment. The invention has a good application prospect in preparation of medicines for preventing or treating tumors.

The application discloses a photosensitive iridium complex with mitochondrial targeting and apoptosis induction and a preparation method thereof, and more particularly discloses a 2,2'-bipyridine compound, a cyclometalated iridium complex comprising the compound as a ligand, a preparation method and application as an antitumor drug. The cyclometalated iridium complex provided by the application takes the 2,2'-bipyridine compound as a ligand, can selectively induce tumor cell apoptosis under light conditions, can be used for preparing an antitumor drug and has great potential value in the field of photodynamic treatment of tumors.

The invention relates to the technical field of biological materials, in particular to a fluorescent probe for targeting mitochondrial G4DNA, a preparation method and fluorescence lifetime imaging application. The fluorescent probe for targeting mitochondrial G4DNA has membrane permeability, high light stability, mitochondrial targeting and selective recognition capability on mtDNA, especially mitochondrial G4 quadruplex (mtG4DNA), and can realize real-time analysis of mtDNA abundance, conformation and mtG4DNA dynamic change under the condition of no need of gene manipulation, fixation or amplification. Through combination of stimulated radiation depletion (STED) or structured illumination super-resolution imaging (SIM) and a fluorescence lifetime imaging microscope (FLIM), the probe can provide intensity and lifetime dual signals at the same time, accurately maps mtDNA aggregate remodeling, oxidative damage and three-dimensional spatial-temporal dynamics participated by a G4 structure, and can be used for detecting the fluorescence lifetime of the mtDNA aggregate. A universal and non-invasive imaging platform is provided for researching related mechanisms of mitochondrial dysfunction, senescence and neurodegenerative diseases (such as ALS).